Pharmaceutical - USA, UK

Filter

Current filters:

USAUK

Popular Filters

Skyepharma will repay 12.7 million euros ahead of Exparel milestone

Skyepharma will repay 12.7 million euros ahead of Exparel milestone

22-09-2014

UK-based Skyepharma, an oral and inhalation drug delivery company, has given notice to CRC European Loan…

AnalgesiaExparelFinancialPacira PharmaceuticalsPharmaceuticalSkyepharmaUKUSA

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Rolf Stahel joins Ergomed as Non-Executive Chairman

Rolf Stahel joins Ergomed as Non-Executive Chairman

07-05-2014

UK-based drug development services company Ergomed has announced the appointment of Rolf Stahel to its…

BiotechnologyBoardroomErgomed Clinical ResarchPharmaceuticalUKUSA

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

07-05-2014

UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created…

BoardroomGW PharmaceuticalsPharmaceuticalUKUSA

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

Medimmune announces research deals with University of Cambridge and University of Texas

Medimmune announces research deals with University of Cambridge and University of Texas

18-03-2014

USA-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

MedImmuneOncologyPharmaceuticalResearchUKUSA

Scancell granted orphan drug designation for melanoma drug

Scancell granted orphan drug designation for melanoma drug

17-02-2014

UK-based immunotherapy company Scancell has been granted orphan drug designation for its SCIB1 ImmunoBody…

ImmunologicalsOncologyPharmaceuticalRegulationScancellSCIB1UKUSA

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

09-01-2014

GlaxoSmithKline (LSE: GSK) says that the US Food and Drug Administration has approved Mekinist (trametinib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlarUKUSA

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

BTG’s varicose vein treatment Varithena gets FDA approval

BTG’s varicose vein treatment Varithena gets FDA approval

27-11-2013

UK specialist health care company BTG (LSE: BTG) has received approval from the US Food and Drug Administration…

BTGPharmaceuticalRegulationUKUSAVarithena

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

15-11-2013

GW Pharmaceuticals (Nasdaq: GWPH) has been granted orphan drug designation by the US Food and Drug Administration…

EuropeGW PharmaceuticalsNorth AmericaPharmaceuticalRare diseasesRegulationUKUSA

Back to top